视黄醇脱氢酶10对经TACE治疗的肝细胞肝癌患者预后的诊断价值

doi:10.3969/j.issn.1671-7171.2022.10.025

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1229 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the value of retinol dehydrogenase 10 (RDH10) in peripheral blood mononuclear cells for the prognosis of hepatocellular carcinoma (HCC) after transhepatic arterial chemoembolization (TACE). 【Methods】A total of 202 HCC patients who were treated in our hospital were divided into the survival group (n=125) and the death group (n=77) according to the 3-year survival prognosis. The fasting venous blood was drawn from patients before TACE (T₁), 3 days after TACE (T₂) and 7 days after TACE (T₃). Ficoll density gradient centrifugation was used to isolate mononuclear cells from peripheral blood. Western blot was used to detect the expression level of RDH10 in mononuclear cells. 【Results】The expression levels of RDH10 in both survival and death groups decreased with time progression. The expression levels of RDH10 at T₂ and T₃ in the survival group were lower than those in the death group (P<0.05). The efficacy of RDH10 at T₃ for predictive prognosis of HCC patients was higher than those of RDH10 at T₁ and RDH10 at T₂; And the differences were statistically significant (P<0.05). COX regression analysis showed that sorafenib and licartin were independent protective factors for the prognosis of HCC patients (P<0.05). The tumor diameter, tumor stage, and RDH10 (T₃) were all independent risk factors for the prognosis of HCC patients (P<0.05). 【Conclusion】The expression level of RDH10 in peripheral blood mononuclear cells on the 7th day after TACE is related to the prognosis of HCC patients, which has certain diagnostic value for the prognosis of TACE treatment.

Key words： Carcinoma, Hepatocellular Chemoembolization, Therapeutic Prognosis

Received: 07 March 2022

PACS:

R735.7

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Jie
	ZHANG Cui-cui

Cite this article:

WANG Jie,ZHANG Cui-cui. Value of Retinol Dehydrogenase 10 in Prognosis of Hepatocellular Carcinoma after TACE Treatment[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(10): 1531-1534.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.10.025 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I10/1531

[1] EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER.EASL clinical practice guidelines:management of hepatocellular carcinoma[J].J Hepatol,2018,69(1):182.
[2] 孙伟航,张骜丹,李巍.预后营养指数联合磁共振表观扩散系数在肝细胞癌肝动脉化疗栓塞中的临床应用价值[J].中华医学杂志,2019,99(3):2581-2585.
[3] BANKOVIC J,STOJSIC J,JOVANOVIC D,et al.Identification of genes associated with non-small-cell lung cancer promotion and progression[J].Lung Cancer,2010,67(2):151-159.
[4] ROSSI E,PICOZZI P,BODEGA B,et al.Forced expression of RDH10 gene retards growth of HepG2 cells[J].Cancer Biol Ther,2007,6(2):238-244.
[5] 中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作委员会,中华医学会肝病学分会肝癌学组.原发性肝癌规范化诊治专家共识[J].临床肿瘤学杂志,2009,14(3):259-269.
[6] 中国医师协会介入医师分会.中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南[J].中华医学杂志,2018,98(47):3811-3819.
[7] 骆杨,霍亮,许家亮,等.细胞核增殖抗原和细胞凋亡调节蛋白在肝细胞癌组织中的表达及其临床意义[J].中华实验外科杂志,2019,36(5):939-942.
[8] 马丽萍,刘小林,张哲雄,等.LAMA4通过TGF-β1/SMAD路径调控肝癌细胞免疫逃逸因子及促进肝癌细胞凋亡[J].免疫学杂志,2019,35(4):300-307.
[9] 解刚强,范永刚,王伟,等.转化生长因子-β1通过诱导Wnt/β-连环蛋白信号通路调节肝癌细胞上皮-间充质转化的研究[J].中华实验外科杂志,2019,36(6):1033-1035.
[10] 张嘉诚,田艳云,杨超,等.利卡汀联合吡柔比星TACE对不可切除肝癌组织中细胞凋亡及上皮间质转化的影响[J].海南医学院学报,2018,24(2):246-249.
[11] 雷海科,李小升,赵玉兰,等.原发性肝癌患者生存预后及影响因素分析(附3106例报告)[J].中华消化外科杂志,2020,19(2):179-184.
[12] 张扬帆,李强,张倜,等.索拉非尼联合与未联合TACE治疗巴塞罗那C期肝细胞癌患者预后分析[J].中华肝胆外科杂志,2020,26(7):526-529.